➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Mallinckrodt
Boehringer Ingelheim
Merck

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,919,461

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,919,461
Title:Erythropoietin receptor peptide formulations and uses
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Inventor(s): Duliege; Anne-Marie (Palo Alto, CA), Stead; Richard (Bellevue, WA), Leuther; Kerstin (San Jose, CA), Woodburn; Kathryn Wynne (Campbell, CA), Naso; Robert Barnett (Menlo Park, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:11/777,500
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,919,461

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No   Start Trial   Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE   Start Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No   Start Trial   Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE   Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No   Start Trial   Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE   Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No   Start Trial   Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Boehringer Ingelheim
AstraZeneca
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.